Table 3 Relationship between PSA value fluctuation rate and prostate cancer risk
1-PSA | Group | Total of follow-up period (person-years) | No. of onset of prostate cancer (case) | Incidence rate of prostate cancer (case/1,000 person-years) | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | ||
|---|---|---|---|---|---|---|---|---|
All | Increase (n = 475) | 1135 | 41 | 36.1 | 1.32 (0.89–1.97) | 1.34 (0.90–1.99) | ||
Reference (n = 914) | 2205 | 60 | 27.2 | 1 | 1 | |||
Decrease (n = 318) | 733 | 11 | 15.0 | 0.55 (0.29–1.04) | 0.562 (0.30–1.07) | |||
4 ng/mL > 1-PSA | Increase (n = 361) | 955 | 11 | 11.5 | 2.91 (1.13–7.51) | * | 2.94 (1.14–7.58) | * |
Reference (n = 656) | 1781 | 7 | 3.9 | 1 | 1 | |||
Decrease (n = 214) | 517 | 2 | 3.9 | 0.98 (0.20–4.72) | 0.94 (0.20–4.53) | |||
4 ng/mL ≤ 1-PSA | Increase (n = 114) | 180 | 30 | 166.6 | 1.36 (0.87–2.14) | 1.43 (0.91–2.26) | ||
Reference (n = 258) | 424 | 53 | 125.0 | 1 | 1 | |||
Decrease (n = 104) | 216 | 9 | 41.7 | 0.35 (0.17–0.71) | ** | 0.36 (0.18–0.74) | ** | |
4 ng/mL ≤ 1-PSA < 10 ng/mL | Increase (n = 97) | 166 | 20 | 120.4 | 1.18 (0.69–2.03) | 1.31 (0.75–2.26) | ||
Reference (n = 222) | 373 | 38 | 101.9 | 1 | 1 | |||
Decrease (n = 70) | 161 | 4 | 24.9 | 0.26 (0.09–0.73) | * | 0.27 (0.10–0.76) | * |